BioCentury | May 12, 2020
Product Development
May 11 Quick Takes: Genfit’s elafibranor misses in NASH Phase III; plus AstraZeneca, Merck, Protalix and TolerogenixX
...transplant rejection therapy In the May 1 issue of The Journal of Clinical Investigation , TolerogenixX GmbH...
...PRX-102) elafibranor (GFT505) AstraZeneca plc Merck & Co. Inc. Protalix BioTherapeutics Inc. Genfit S.A. Alpha galactosidase A Peroxisome proliferation activated receptor (PPAR) delta TolerogenixX GmbH...
...PRX-102) elafibranor (GFT505) AstraZeneca plc Merck & Co. Inc. Protalix BioTherapeutics Inc. Genfit S.A. Alpha galactosidase A Peroxisome proliferation activated receptor (PPAR) delta TolerogenixX GmbH...
